Long-Term Data Support Early GA Intervention

New data from the GATHER2 open-label extension, presented during retina subspecialty day at AAO, emphasizes the value of starting treatment early to preserve retinal tissue.

By: Arshad M. Khanani, MD, MA, FASRS, Diana V. Do, MD

Retinal Physician October 18, 2025

5 Key Takeaways

1

Early intervention in geographic atrophy treatment preserves retinal tissue and reduces lesion growth.
2

The GATHER2 trial's open-label extension showed a 40.5% reduction in GA lesion growth with monthly ACP treatment.
3

Patients previously treated with sham also benefited, showing a 37.1% reduction in lesion growth after switching to ACP.
4

Starting ACP treatment early is crucial for maximizing retinal tissue preservation and treatment efficacy.
5

Flexibility in treatment frequency can accommodate patient needs while maintaining similar efficacy outcomes.

Diana V. Do, MD

Retina Specialist

Specialties: Ophthalmology

Bio: Diana V. Do, MD, is a retina specialist and author for Retinal Physician. Her work focuses on ophthalmology and retinal disease, with interest in clinical trials, practice management, and emerging therapies for retinal conditions. In her Retinal Physician column, Dr. Do discusses developments in retina care, including clinical research collaboration, international clinical trial infrastructure, and investigational treatments for neovascular age-related macular degeneration and diabetic macular edema. She has also referenced her training connections with the Wilmer Eye Institute.

PentaVision

Retinal Physician

Long-Term Data Support Early GA Intervention

5 Key Takeaways

1

2

3

4

5

Recommendations